What infections are patients most at risk for on Cosentyx (secukinumab)?
Cosentyx (secukinumab) is a monoclonal antibody that blocks IL‑17A signaling. Because IL‑17 helps protect against certain infections, Cosentyx can increase the risk of infections in general, and may be particularly relevant for fungal infections such as mucocutaneous candidiasis (yeast infections).
What infections have been seen in clinical use?
Across clinical experience with IL‑17 inhibitors, the infection signal most commonly discussed with this class is fungal infection (including Candida-type infections). Patients may notice symptoms such as oral thrush, trouble swallowing from mouth/throat yeast, or other recurring skin or mucosal yeast symptoms.
Other infections can occur as well, and the overall guidance is to watch for signs of infection during treatment (for example fever, chills, persistent cough, burning with urination, or new/worsening localized pain or swelling).
Who has higher risk of serious infection?
Risk tends to be higher when patients have one or more of the following:
- Ongoing or recent infections
- A history of recurrent infections
- Diabetes or other conditions that impair immune defenses
- Concomitant immunosuppressive therapies (depending on what is being used alongside Cosentyx)
- Use in settings where infection exposure is more likely
Clinicians also consider tuberculosis (TB) risk before starting biologics that affect immune pathways, since TB can reactivate under immunomodulatory treatment.
What should patients do if they get an infection while on Cosentyx?
If an infection develops, patients should contact their clinician promptly. In practice, clinicians commonly evaluate:
- Whether the infection is mild and resolving or worsening
- Whether treatment should be held temporarily
- Whether infection-specific therapy is needed (for example antifungals for candidiasis)
- Whether any additional immune suppression is contributing
Do not ignore symptoms such as fever, shortness of breath, or rapidly worsening skin findings.
How do clinicians screen before starting Cosentyx to lower infection risk?
Before the first dose, clinicians typically assess infection history and may test for TB and check for other relevant infection risks as part of pre-biologic safety workups. This helps reduce the chance of starting treatment in someone with an active infection or a risk that could reactivate.
Does Cosentyx differ from other biologics in infection risk?
Cosentyx’ infection profile is most closely associated with IL‑17 pathway effects, where Candida-type fungal infections are a recurring theme across IL‑17 inhibition. Exact rates vary by patient population and study, and the comparison with other biologics depends on the background therapies and underlying disease.
What about drug interactions and vaccines?
Infection risk can also be influenced by what else the patient is taking (such as other immunosuppressants). For vaccines, live vaccines are generally avoided during biologic therapy, while inactivated vaccines are usually preferred. The best approach depends on a patient’s vaccination status and timing relative to treatment.
---
If you tell me your situation—what condition you’re taking Cosentyx for, whether you’ve had infections (especially yeast/TB), and any other meds you take—I can narrow the most relevant infection risks and what to watch for.
Sources:
No DrugPatentWatch.com or other sources were provided in the prompt.